We create minimally invasive medical technology addressing patient needs from diagnosis to therapy.
“We Think Big by Creating Small”
FOR IMMEDIATE RELEASE: December 11, 2017
TransMed7, LLC Announces Inaugural Members of its Business Advisory Board
Portola Valley, CA, December 11, 2017; TransMed7, LLC today announced the creation of, and inaugural appointments to, its Business Advisory Board (BAB). The TransMed7 BAB is composed of accomplished business experts offering innovative advice and dynamic perspectives that will contribute to the accomplishment of TransMed7’s tactical goals and strategic objectives. These experts represent a carefully selected group of proven innovators, each of whom has already established his or her reputation based on high ethical standards, demonstrated leadership, and a willingness to embrace and support a mission for the good of others. The Members of the BAB provide TransMed7’s Senior Management Team with expanded business perspectives in a constantly changing environment, and each Member brings a focus and particular emphasis on one or more of a number of business sectors, including but not limited to the following areas:
- Strategic Planning, including Tactical Execution;
- Commercial Launch of new Platform Technologies;
- S. and O.U.S.-based Distributors and Sales Networks;
- Corporate Relations Analysis and Development;
- International Business Management and Strategic Market Development;
- Financial Management, Fundraising and Investment Performance Options;
- Corporate Compliance and Tax Planning Advice; and
- Public Relations, Networking, Communications and Advocacy.
“We are honored to have these internationally recognized leaders as the founding members of our Business Advisory Board”, commented Eugene H. Vetter, TransMed7 CEO and Chairman of the BAB. “In addition to their individual business perspectives, they bring additional experience as founders, inventors, and entrepreneurs to our organization and will be integral to TransMed7’s commercial launch of our critically needed, minimally-invasive medical technologies to get them into the hands of clinicians for the benefit of their patients around the world as rapidly as possible.”
The inaugural members include:
Tony Astorga – Mr. Astorga actively serves on several both public and private boards including his current position as Chairman of the Board at the Arizona Hispanic Chamber of Commerce Foundation. He also serves as a financial consultant to AZTOR Health and Wealth Management Advisors. Mr. Astorga formerly served as Senior Vice President, CFO, and Chief Business Development Officer for Blue Cross Blue Shield (BCBS) of Arizona as well as the President of BCBS of Mexico. A graduate of Arizona State University with a Bachelor in Accounting, Mr. Astorga is a CPA and former founding partner of Astorga and Maurseth, Certified Public Accountants.
Mark Bradley – Most recently Mr. Bradley served as CEO and Board Member of Conversica; one of the fastest growing artificial intelligence companies in the world. He currently serves on several boards in the technology and education sectors including the Southern Methodist University (SMU) Lyle School of Engineering. Prior to this, Mr. Bradley was a Co-Founder, President, and Senior Vice President of Global Product Shopping/International/Operations of NexTag, known for its popular consumer website providing price comparison shopping information and which exited in 2007 for $1.3B after opening successful operations in 9 countries. Mr. Bradley is a graduate of Southern Methodist University with a Bachelor in Finance.
Carlos Collazo – Starting from his facilitating creation of the current Standard International Trade Commodity Classification System, Mr. Collazo has leveraged his expertise to found and/or lead several successful technology companies. These include Mariner Systems Incorporated (MARSYS) where he was the Founder, CEO, and Chairman until it was sold in 2013. The MARSYS Group of companies consisted of associated companies in the information technology and services industry and delivered technology services to Fortune 500 companies in over 20 countries for more than 30 years. The derivative works from the core technologies developed under Mr. Collazo’s leadership are still in productive use in the market via licenses and/or acquisitions and include applications to cyber security, systems optimization, digital media, data analytics, education, trade systems and others. Mr. Collazo has served on the boards of several educational institutions and leadership councils including Notre Dame University and the Cyber Intelligence Initiative. He is a graduate of Oklahoma State University.
Thomas Cowan – Mr. Cowan is Director of The Center for Technology Management at Columbia University and most recently served as CEO at modomodo, a SaaS mobile application development platform company. Mr. Cowan is recognized as a technology CEO and entrepreneur creating value through execution with particular expertise in enterprise software, Big Data analytics, and SaaS delivery. He spent more than two decades at IBM starting in Finance and moving to CFO and GM roles. He subsequently served as Chairman and CEO of OutlookSoft, a leading developer of business performance software, and positioned the company for its acquisition by SAP. At Vcommerce, a pioneer developer of e-commerce software, Mr. Cowan served as Chairman/CEO/COO/CFO where he led a successful restructuring and which established the basis for later acquisition by Google. Mr. Cowan has served on numerous public and private boards including SMTC Corporation, Wake Forest University, and Tivoli Systems. He is the author of From Idea to Business, Business Basics, and Leadership Basics. He received his Bachelor in Economics from Wake Forest University and an MBA from the University of South Carolina.
“Each of the inaugural members of our BAB bring years of successful experience across many of the important industries related to and supportive of TransMed7’s mission (“to efficiently design, develop, and deliver transformational, minimal access medical devices which address patient needs from diagnosis to therapy”),” said Dr. Edgar D. Staren, President of TransMed7 and Executive Chairman of the BAB. “We are grateful for their willingness to serve as BAB members and look forward to benefitting from their judgment and counsel.”
In anticipation of 510(k) clearance expected in the first quarter, 2018, TransMed7 is finalizing production and market introduction strategies for its SpeedBird™ soft tissue biopsy product platform and its Concorde™ platform technology for stereotactic and MRI based biopsy procedures, with rollout for both domestic and international sales and distribution. In addition, the BAB will provide crucial guidance as TransMed7 continues development of its portfolio of next generation products based on innovative variations of its patented “Zero5” working element, which include: Cardinal™, a fine-needle core biopsy device designed for breast, thyroid, and lymph nodes; and Cygnet™, a novel device designed to establish continued access for intervention including aspiration and biopsy of bone marrow. TransMed7 is also currently developing Martinet™, a revolutionary new minimal access device designed for complete removal of target tissue.